blog
Last updated: 2024-12-20

Key to High Aggressiveness of Pancreatic Cancer Identified!

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Key to High Aggressiveness of Pancreatic Cancer Identified!

Key to High Aggressiveness of Pancreatic Cancer Identified!

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

[Identifying the Key to High Invasiveness in Pancreatic Cancer]

Research reveals that the Galectin-1 protein plays a significant role in the cells surrounding tumors, promoting fibroblast activation and influencing tumor growth and metastasis, while also contributing to treatment resistance.

Key Data:

  • The five-year survival rate for pancreatic cancer is only 10%.
  • Activated fibroblasts promote tumor growth and increase cancer invasiveness.
  • The research findings open up possibilities for new therapies targeting Galectin-1, warranting further exploration.

For more details, please visit: https://tinyurl.com/2avz2rpe

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Cancer Information

Related Reading